Molecular Partners licenses retinal diseases drug to Allergan
MP0112 is a phase II proprietary therapeutic DARPin protein targeting VEGF under experiment for the treatment of retinal diseases. Under the pact, Molecular Partners and Allergan will jointly
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.